China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class ASZSE: 300294

China Resources Boya Bio-pharmaceutical Group: Q1 2026 saw steep declines in revenue and profit amid fierce competition and policy changes

· Issued by China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

Revenue and net profit dropped sharply year-over-year in Q1 2026 due to intensified competition and procurement policies, with core product sales and prices falling. Cash flow from operations turned negative, and VAT rate hikes may further pressure profitability.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

All China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A news releases